Skip to ContentSkip to Navigation
Over ons Praktische zaken Waar vindt u ons dr. M. (Hilde) Jalving

Publicaties

A comparison of real-world data on adjuvant treatment in patients with stage III BRAF V600 mutated melanoma – Results of systematic literature research

Adjuvant immunotherapy in the modern management of resectable melanoma: current status and outlook to 2028

Change in Metabolic Markers and the Risk of Skin Cancer: Results from the Lifelines Cohort Study in the Netherlands

Immune checkpoint inhibitor-mediated polymyalgia rheumatica versus primary polymyalgia rheumatica: comparison of disease characteristics and treatment requirement

128P - Whole blood transcriptomics identifies transcriptional patterns linked to outcomes in patients receiving immune checkpoint inhibitors

B cells critical for outcome in high grade serous ovarian carcinoma

Causality and functional relevance of BRCA1 and BRCA2 pathogenic variants in non-high-grade serous ovarian carcinomas

Cemiplimab in locally advanced or metastatic cutaneous squamous cell carcinoma: prospective real-world data from the DRUG Access Protocol

Desensitisatie als behandeloptie bij hypersensitiviteit voor antitumormedicijnen

Dosering van dexamethason rond pemetrexed kan lager

Pers/media

‘De cieDD is als voorbeeld gaan dienen voor de portal’

'NADINA-studie toegelicht door dr. Hilde Jalving'

MEDtalks - Melanoomupdate 2024

Environmental impact to be included in package leaflets accompanying medication

European Oncologists Are Thinking Green

“Green” prescribing may limit the environmental impact of oncology

MEDtalks E-learning; Zeldzame melanomen en huidtumoren